Bloomberg News

Sanofi, Regeneron Say Antibody Fights Bad Cholesterol in Study

March 27, 2012

Sanofi and partner Regeneron Pharmaceuticals Inc. (REGN:US) said an experimental monoclonal antibody showed promising results in a mid-stage clinical test, helping reduce patients’ so-called bad cholesterol levels. The companies presented the trial results yesterday at the American College of Cardiology meeting in Chicago, they said in a statement.

To contact the editor responsible for this story: Marthe Fourcade at mfourcade@bloomberg.net


Best LBO Ever
LIMITED-TIME OFFER SUBSCRIBE NOW

Companies Mentioned

  • REGN
    (Regeneron Pharmaceuticals Inc)
    • $355.47 USD
    • 9.44
    • 2.66%
Market data is delayed at least 15 minutes.
 
blog comments powered by Disqus